164 related articles for article (PubMed ID: 38398600)
1. Characterizing Aptamer Interaction with the Oncolytic Virus VV-GMCSF-Lact.
Dymova MA; Malysheva DO; Popova VK; Dmitrienko EV; Endutkin AV; Drokov DV; Mukhanov VS; Byvakina AA; Kochneva GV; Artyushenko PV; Shchugoreva IA; Rogova AV; Tomilin FN; Kichkailo AS; Richter VA; Kuligina EV
Molecules; 2024 Feb; 29(4):. PubMed ID: 38398600
[TBL] [Abstract][Full Text] [Related]
2. Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy.
Kochneva G; Sivolobova G; Tkacheva A; Grazhdantseva A; Troitskaya O; Nushtaeva A; Tkachenko A; Kuligina E; Richter V; Koval O
Oncotarget; 2016 Nov; 7(45):74171-74188. PubMed ID: 27708236
[TBL] [Abstract][Full Text] [Related]
3. Transcriptome Changes in Glioma Cells upon Infection with the Oncolytic Virus VV-GMCSF-Lact.
Semenov DV; Vasileva NS; Dymova MA; Mishinov SV; Savinovskaya YI; Ageenko AB; Dome AS; Zinchenko ND; Stepanov GA; Kochneva GV; Richter VA; Kuligina EV
Cells; 2023 Nov; 12(22):. PubMed ID: 37998351
[TBL] [Abstract][Full Text] [Related]
4. Electrochemical differentiation of epitope-specific aptamers.
Labib M; Zamay AS; Muharemagic D; Chechik AV; Bell JC; Berezovski MV
Anal Chem; 2012 Mar; 84(5):2548-56. PubMed ID: 22324738
[TBL] [Abstract][Full Text] [Related]
5. Recombinant Vaccinia Viruses Coding Transgenes of Apoptosis-Inducing Proteins Enhance Apoptosis But Not Immunogenicity of Infected Tumor Cells.
Koval O; Kochneva G; Tkachenko A; Troitskaya O; Sivolobova G; Grazhdantseva A; Nushtaeva A; Kuligina E; Richter V
Biomed Res Int; 2017; 2017():3620510. PubMed ID: 28951871
[TBL] [Abstract][Full Text] [Related]
6. The Signaling Pathways Controlling the Efficacy of Glioblastoma Therapy.
Vasileva NS; Ageenko AB; Richter VA; Kuligina EV
Acta Naturae; 2022; 14(2):62-70. PubMed ID: 35923561
[TBL] [Abstract][Full Text] [Related]
7. Double Recombinant Vaccinia Virus: A Candidate Drug against Human Glioblastoma.
Vasileva N; Ageenko A; Dmitrieva M; Nushtaeva A; Mishinov S; Kochneva G; Richter V; Kuligina E
Life (Basel); 2021 Oct; 11(10):. PubMed ID: 34685455
[TBL] [Abstract][Full Text] [Related]
8. Multifunctional electrochemical aptasensor for aptamer clones screening, virus quantitation in blood and viability assessment.
Labib M; Zamay AS; Berezovski MV
Analyst; 2013 Mar; 138(6):1865-75. PubMed ID: 23381386
[TBL] [Abstract][Full Text] [Related]
9. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
[TBL] [Abstract][Full Text] [Related]
10. Electrochemical sensing of aptamer-facilitated virus immunoshielding.
Labib M; Zamay AS; Muharemagic D; Chechik A; Bell JC; Berezovski MV
Anal Chem; 2012 Feb; 84(3):1677-86. PubMed ID: 22242920
[TBL] [Abstract][Full Text] [Related]
11. Aptamers Enhance Oncolytic Viruses' Antitumor Efficacy.
Dymova MA; Kichkailo AS; Kuligina EV; Richter VA
Pharmaceutics; 2022 Dec; 15(1):. PubMed ID: 36678780
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
Deng L; Fan J; Guo M; Huang B
Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
[TBL] [Abstract][Full Text] [Related]
13. Anti-Fab aptamers for shielding virus from neutralizing antibodies.
Muharemagic D; Labib M; Ghobadloo SM; Zamay AS; Bell JC; Berezovski MV
J Am Chem Soc; 2012 Oct; 134(41):17168-77. PubMed ID: 23016897
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic Vaccinia Virus Gene Modification and Cytokine Expression Effects on Tumor Infection, Immune Response, and Killing.
Inoue T; Byrne T; Inoue M; Tait ME; Wall P; Wang A; Dermyer MR; Laklai H; Binder JJ; Lees C; Hollingsworth R; Maruri-Avidal L; Kirn DH; McDonald DM
Mol Cancer Ther; 2021 Aug; 20(8):1481-1494. PubMed ID: 34045231
[TBL] [Abstract][Full Text] [Related]
15. Single-particle characterization of oncolytic vaccinia virus by flow virometry.
Tang VA; Renner TM; Varette O; Le Boeuf F; Wang J; Diallo JS; Bell JC; Langlois MA
Vaccine; 2016 Sep; 34(42):5082-5089. PubMed ID: 27614781
[TBL] [Abstract][Full Text] [Related]
16. Aptamer-facilitated Protection of Oncolytic Virus from Neutralizing Antibodies.
Muharemagic D; Zamay A; Ghobadloo SM; Evgin L; Savitskaya A; Bell JC; Berezovski MV
Mol Ther Nucleic Acids; 2014 Jun; 3(6):e167. PubMed ID: 24892725
[TBL] [Abstract][Full Text] [Related]
17. An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy.
Shi Z; Liu B; Huang C; Xie W; Cen Y; Chen L; Liang M
Biochem Biophys Res Commun; 2021 Jun; 559():176-182. PubMed ID: 33945995
[TBL] [Abstract][Full Text] [Related]
18. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy.
Yu F; Wang X; Guo ZS; Bartlett DL; Gottschalk SM; Song XT
Mol Ther; 2014 Jan; 22(1):102-11. PubMed ID: 24135899
[TBL] [Abstract][Full Text] [Related]
19. Generation of novel oncolytic vaccinia virus with improved intravenous efficacy through protection against complement-mediated lysis and evasion of neutralization by vaccinia virus-specific antibodies.
Lee N; Jeon YH; Yoo J; Shin SK; Lee S; Park MJ; Jung BJ; Hong YK; Lee DS; Oh K
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36717184
[TBL] [Abstract][Full Text] [Related]
20. Profiling Additional Effects of Aptamer Fluorophore Modification on Microscale Thermophoresis Characterization of Aptamer-Target Binding.
Yu H; Zhao Q
Anal Chem; 2023 Nov; 95(46):17011-17019. PubMed ID: 37946406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
